Intellia Therapeutics Inc (FRA:38I)
€ 11.365 -0.31 (-2.66%) Market Cap: 1.17 Bil Enterprise Value: 635.81 Mil PE Ratio: 0 PB Ratio: 1.27 GF Score: 56/100

Intellia Therapeutics Inc at Bank of America Global Healthcare Conference Transcript

May 09, 2023 / 09:20PM GMT
Release Date Price: €39.92 (+1.94%)
Gregory Allen Harrison
BofA Securities, Research Division - Analyst

Hello, and welcome to Day 1 of the Bank of America Healthcare Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And today, we have Intellia Therapeutics with us and representing Intellia is Ian Karp, SVP of IR and Corporate Communications. Ian, would you like to start off with some opening remarks, then we'll jump into Q&A.

Ian Karp
Intellia Therapeutics, Inc. - SVP of IR & Corporate Communications

Sure. And thanks so much for having us. Yes, Intellia for those that are a bit new to Intellia, we're one of the leading full spectrum genome managing companies, which really means 3 things. So we're focused in 3 core areas, which is building out a deep gene editing capability and a toolbox that we can use for therapeutic purposes, and we then deploy those tools both on the in vivo and ex vivo side of human therapeutics. So on the in vivo side, we're actually delivering the CRISPR machinery to make those edits typically for -- to address disease-causing proteins or

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot